Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants.
Saved in:
| Title: | Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants. |
|---|---|
| Authors: | Cui C; Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China.; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China., Niu X; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China., Li H; Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China.; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China., Zhang R; Department of Clinical Pharmacology, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China., Geng L; Department of Clinical Pharmacology, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China., Lin W; Department of Clinical Operations, Shenzhen Salubris Pharmaceuticals Co. Ltd, Shenzhen, 518000, China., Liu Z; Department of Data Science, Shenzhen Salubris Pharmaceuticals Co. Ltd, Beijing, 100022, China., Wang X; Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China. sshwang@126.com., Liu D; Drug Clinical Trial Centre, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com.; Centre of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com.; Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com. |
| Source: | Clinical drug investigation [Clin Drug Investig] 2025 Apr; Vol. 45 (4), pp. 179-189. Date of Electronic Publication: 2025 Mar 13. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
